ReviewCardiac failure review2018
Bromocriptine for the Treatment of Peripartum Cardiomyopathy.
Review in Cardiac failure review, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 1 synthesis or guideline pooled it, 42 citations in OpenAlex.
- Prevalence and associated outcomes of right ventricular dysfunction in peripartum cardiomyopathy: a systematic review, meta-analysis and meta-regression.Open heart · 2025Pooled it
- Real-world clinical validation study: individualized warfarin dosing strategy integrating genetic polymorphisms and Bayesian.Naunyn-Schmiedeberg's archives of pharmacology · 2026Article
- Management of Peripartum Cardiomyopathy With and Without Bromocriptine: A Comparative Study.Cureus · 2026Article
- Peripartum cardiomyopathy in an intensive care unit setting.World journal of critical care medicine · 2026Review
- Addressing maternal cardiovascular risk: The impact of lactation, adverse pregnancy outcomes, and racial disparities.American heart journal plus : cardiology research and practice · 2025Article
- Caring for Two: Management of the Critically Ill Cardiac Patient During Pregnancy.JACC. Advances · 2025Review
- Unraveling the mystery of peripartum cardiomyopathy; Cathepsin D.American heart journal plus : cardiology research and practice · 2025Article
- Pregnancy-Associated Takotsubo Syndrome: A Narrative Review of the Literature.Journal of clinical medicine · 2025Review
- Peripartum cardiomyopathy in the twenty-first century: a review of the pathophysiology and clinical trials for novel disease-specific therapeutics.Heart failure reviews · 2025Review
- Pregnancy-Associated Cardiomyopathy in a Late-Diagnosed Partial Hydatidiform Mole: A Case Report.Case reports in obstetrics and gynecology · 2025Article
- Peripartum cardiomyopathy: a comprehensive and contemporary review.Heart failure reviews · 2024Review
- Pharmacological interventions for peripartum cardiomyopathy.The Cochrane database of systematic reviews · 2024Article
- Preeclamptic heart failure - perioperative concerns and management: a narrative review.Perioperative medicine (London, England) · 2024Review
- Bromocriptine: does this drug of Parkinson's disease have a role in managing cardiovascular diseases?Annals of medicine and surgery (2012) · 2024Review
- Connecting the Dots: Exploring the Interplay Between Preeclampsia and Peripartum Cardiomyopathy.Journal of pregnancy · 2024Review
- Primary takotsubo syndrome with recurrent prolactinoma.Journal of cardiology cases · 2023Article
- The role of prolactin/vasoinhibins in cardiovascular diseases.Animal models and experimental medicine · 2023Review
- Maternal critical care: part II.BJA education · 2021Review
- Review
- Peripartum Cardiomyopathy: A Review.Current emergency and hospital medicine reports · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Peripartum cardiomyopathy (PPCM) is a life-threatening, pregnancy-associated heart disease that develops towards the end of pregnancy or in the first months following delivery in previously healthy women. Understanding of the pathophysiology has progressed in recent years, highlighting an oxidative-stress mediated cleavage of the nursing hormone prolactin into a toxic 16-kDa prolactin fragment as a major factor driving the disease. The 16-kDa prolactin fragment induces detrimental but potentially reversible effects on heart function. Bromocriptine, a clinically-approved drug to block prolactin release, was initially tested in a PPCM mouse model where it efficiently prevented the onset of PPCM. Consequently, this treatment concept was transferred to and successfully used in humans as a bench-tobedside approach. Encouraging proof-of-concept studies led to a randomised trial that further strengthens the role of bromocriptine in addition to standard heart failure therapy in clinical practice. The aim of this article is to summarise this novel and disease-specific medical treatment, along with current knowledge on the epidemiology and pathophysiology of PPCM.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.